| 11.22 0.39 (3.6%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.64 | 1-year : | 14.64 |
| Resists | First : | 11.68 | Second : | 12.53 |
| Pivot price | 11.26  |
|||
| Supports | First : | 10.3 | Second : | 8.56 |
| MAs | MA(5) : | 10.86 |
MA(20) : | 11.44 |
| MA(100) : | 11.63 |
MA(250) : | 9.45 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 26.6 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 13.85 | Low : | 5.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCUL ] has closed above bottom band by 46.9%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.25 - 11.33 | 11.33 - 11.39 |
| Low: | 10.63 - 10.72 | 10.72 - 10.78 |
| Close: | 11.11 - 11.24 | 11.24 - 11.34 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Mon, 10 Nov 2025
RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory - Yahoo! Finance Canada
Sat, 08 Nov 2025
Why Ocular Therapeutix (OCUL) Is Down 6.9% After Wider Losses Despite SOL-R Trial Milestone - simplywall.st
Fri, 07 Nov 2025
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 07 Nov 2025
Analyst Estimates: Here's What Brokers Think Of Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Third-Quarter Report - Yahoo Finance
Wed, 05 Nov 2025
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Tue, 04 Nov 2025
Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Call Highlights: - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 212 (M) |
| Shares Float | 150 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 74.4 (%) |
| Shares Short | 13,590 (K) |
| Shares Short P.Month | 15,280 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.76 |
| Profit Margin | 0 % |
| Operating Margin | -502.6 % |
| Return on Assets (ttm) | -31.2 % |
| Return on Equity (ttm) | -63.5 % |
| Qtrly Rev. Growth | -18.2 % |
| Gross Profit (p.s.) | -0.58 |
| Sales Per Share | 0.26 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -176 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -8.91 |
| PEG Ratio | 0 |
| Price to Book value | 6.33 |
| Price to Sales | 41.96 |
| Price to Cash Flow | -13.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|